Novel Myelofibrosis Drug is “Versatile” for Managing Anemia
DISC‑0974 showed meaningful hemoglobin increases in both patients with JAK‑inhibitor‑treated and untreated myelofibrosis with anemia.
Investigational anti‑hemokuvelin monoclonal antibody DISC‑0974 demonstrated clinically meaningful hemoglobin increases in patients with myelofibrosis–related anemia, irrespective of prior JAK‑inhibitor exposure (phase 2 RALLY‑MF).
The ability to raise hemoglobin in both JAK‑inhibitor‑treated and untreated patients indicates that DISC‑0974 can be used as a monotherapy or combined with existing JAK‑inhibitors, potentially enabling patients to stay on their current therapy longer and improving anemia management in myelofibrosis.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
- Population Pharmacokinetics and Exposure‑Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
- SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
- Current treatments, practical management, and emerging investigational therapies for myelofibrosis